131 results
Page 5 of 7
6-K
5bae1ew6cuk as4ld
24 Sep 09
Results of Adagio Study with Azilect? In Parkinson???s Disease Published In New England Journal of Medicine
12:00am
6-K
nau9r1j
29 Jun 09
Teva Completes Enrollment In Second Oral Laquinimod Phase III MS Clinical Trial
12:00am
6-K
mws cb62s
28 Apr 09
New Data Illustrate Novel Mechanism of Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis
12:00am
6-K
aukkvs4q3hm
17 Feb 09
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by Fda
12:00am
6-K
2ynlladb
5 Dec 08
Current report (foreign)
12:00am
6-K
mywq1
19 Nov 08
Teva Completes Enrollment In Laquinimod Phase III Clinical Trial
12:00am
F-4/A
8mml4usm
14 Oct 08
Registration of securities (foreign) (amended)
12:00am
6-K
kycx5bhng0 zm31lvw
16 Sep 08
Teva to Present New Treatment Data at World Congress for Multiple Sclerosis
12:00am
F-4
qhfffh67w otyb
16 Sep 08
Registration of securities (foreign)
12:00am
6-K
EX-2
r53z8v6nxmet2f v0
18 Jul 08
Report of Foreign Private Issuer
12:00am
425
EX-2.1
l3k4xnn9
18 Jul 08
Business combination disclosure
12:00am
6-K
dv4zhobm5s
16 Jul 08
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
12:00am
6-K
npukitfh7m m5hro55
7 Jul 08
Teva Provides Update on Forte Trial
12:00am
6-K
v3ha0r82
30 Jun 08
Teva & Anp Announce That ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrated Significant Reduction In Disease Activity
12:00am
6-K
eq6l81re9yorby15quw9
10 Apr 08
Copaxone? Significantly Reduced Annual Relapse Rates and Stabilized Disease Progression In Relapsing Remitting Multiple Sclerosis Patients Failing Interferon Treatment
12:00am
6-K
1g12 d10xaj
7 Nov 07
Initiation of Enrollment In Pivotal Phase III Clinical Study of Oral Laquinimod for Relapsing-remitting Multiple Sclerosis
12:00am
6-K
eappqmynhrlf
2 Nov 07
Current report (foreign)
12:00am